Insulet raised its revenue expectations for 2026 as the company brings more users onto its insulin patch pumps.
The diabetes technology company now expects total revenue growth of 21% to 23% for the year on a constant currency basis, up from a previous range of 20% to 22%, CEO Ashley McEvoy told investors Wednesday.
Most of the growth comes from Insulet’s expectations for international sales, while the company’s outlook for U.S. sales remains unchanged.
In European markets where Insulet has an established presence, such as the U.K., France and Germany, the company brought in more new customers, McEvoy said. Insulet is also switching more people over from its lower cost Omnipod Dash device to its newer Omnipod 5 system.
In the U.S., Insulet had a more challenging quarter. New customer starts increased compared with the year-ago period, but decreased from the end of 2025. McEvoy attributed the change to insurance deductibles resetting at the start of the year.
The CEO said Insulet is working on the sixth generation of its Omnipod device, which it expects to launch in 2027, and is also making progress on a fully closed loop system for people with Type 2 diabetes.
Recall update
McEvoy fielded questions from investors about a March recall of Insulet’s Omnipod 5 devices, after the company found that certain lots of the insulin patch pumps may have a tear in the internal tubing. In April, Insulet provided another update, expanding the list of affected products to include expired devices.
Insulet reported 29 serious injuries associated with the problem as of April 17, according to the Food and Drug Administration. McEvoy said no additional adverse events had been reported since the company’s April update.
The company reported about $12 million of expenses associated with the recall in the first quarter, CFO Flavia Pease said in the earnings call.
McEvoy said she did not think the recall affected new customer starts in the first quarter.
“In our industry, it's not possible to eliminate all risks, but what matters most is how issues are identified and addressed,” McEvoy said. “And in this case, we got after it early.”
The CEO said that Insulet plans to strengthen its quality systems and operating controls.
